Gain an Insight in to the European Central Nervous System Therapeutics Markets

Research and Markets (http://www.researchandmarkets.com/reports/c50528) has announced the addition of the new Frost & Sullivan Report “European Central Nervous System (CNS) Therapeutics Markets” to their offering.

This Frost & Sullivan research service titled “European Central Nervous System (CNS) Therapeutics Markets” provides a detailed analysis of various neurological and psychiatric disorders. It provides a qualitative analysis of key drivers, restraints and trends, as well as detailed market forecasts of individual disorder segments and country-wise trends. It also consists of strategic recommendations to market participants to gain an advantage in the highly competitive market. In this research, Frost & Sullivan expert analysts thoroughly examine the following markets: anti-Alzheimer drugs, anti-Parkinsonian drugs, antiepileptics, pain management drugs, antidepressants, and antipsychotics.

Market Overview

Increasing Ageing Population to Result in Greater Incidence of CNS Disorders

The prevalence of central nervous system (CNS) disorders in the European population, which represents a significant component of overall healthcare expenses, is exhibiting a steady rise. Further, improving diagnostic techniques and growing awareness of these disorders are likely to result in an enhanced focus on the CNS therapeutics market. The ageing population is also expected to support market growth, as age is likely to be the most significant non-genetic risk factor contributing to most CNS disorders. In addition, the present lack of drugs to cater to the increasing number of patients diagnosed with CNS disorders offers tremendous scope to support new blockbuster products.

The market for psychiatric disorders features a high level of competition, thereby resulting in a shift in focus to neurological disorders, states the analyst of this research service. Accordingly, overall market growth will rely on the performance of segments such as Alzheimer disease and multiple sclerosis. While no effective long-term treatment exists for diseases such as Alzheimer’s and Parkinson’s, the antipsychotics market also features a large proportion of patients hampered by side effects of drugs. Hence, the high level of unmet clinical needs effectively offers tremendous potential for the development of the CNS therapeutics market as a whole.

Improved Focus on Product Life-cycle Management to Assist in Market Expansion

In keeping with escalating healthcare costs, nations across Europe are implementing strategies to curtail overall costs, thus affecting the profit margins of pharmaceutical companies. Moreover, market penetration will prove difficult due to factors such as generic substitution, parallel reimportation and reference pricing. The National Institute of Clinical Excellence (NICE) guidelines for multiple sclerosis and oral neuroleptics in the United Kingdom and the decentralisation of reimbursement policies in Italy are certain decisions that are likely to have significant ramifications on the market, remarks the analyst.

Product life-cycle management will become essential, particularly in the context of mature markets such as depression and psychosis. At the same time, research should focus on expanding product indications as well as sustaining the market shares of blockbuster molecules. In addition, focusing on emerging lifestyle-related CNS disorders such as smoking cessation, pre-menstrual depressive disorder (PMDD) and erectile dysfunction is expected to favourably impact market expansion. Moreover, marketing collaborations and consolidation through mergers and acquisitions will aid in offsetting the risks of drug development. Market participants would also do well to concentrate on novel drug delivery methods to exploit existing opportunities for market growth.

For more information, visit http://www.researchandmarkets.com/reports/c50528